Top

Published in:

01-04-2013 | Original Article

Cystatin C in children on chronic hemodialysis

Authors: Olivera Marsenic, Andrea Wierenga, Donna R. Wilson, Michael Anderson, Tripti Shrivastava, Garfield A. Simon, Anne M. Beck, Tiffany J. Swanson, Kathleen Studnicka, Dorit Elberg, Kevin Couloures, Martin A. Turman

Published in: Pediatric Nephrology | Issue 4/2013

Abstract

Background

Cystatin C (CyC) concentration has been suggested as a marker of middle-molecule accumulation, hemodialysis (HD) adequacy and for estimating residual renal function (RRF), but it has not been studied in pediatric HD. High CyC is associated with increased cardiovascular disease (CVD). We investigated CyC kinetics and the effect of RRF on CyC in a pediatric HD population.

Methods

A total of 21 HD sessions and 20 interdialytic periods were analyzed in seven patients, age 5–19 years, of whom four were anuric (A) and three were non-anuric (NA). CyC was measured before (preHD) and after (postHD) three standard HD sessions in 1 week and prior to the first session of the following week.

Results

We found no difference (p = 0.67) in CyC concentration between preHD CyC (9.85 ± 2.15 mg/l; A vs. NA, p = 0.37) and postHD CyC (10.04 ± 2.83 mg/l; A vs NA, p = 0.28). The weekly average preHD CyC median concentration was 10.14 mg/l (A vs. NA, p = 0.87) and correlated with age (r = 0.808, p = 0.03) and height measurement (r = 0.799, p = 0.03), but not with RRF, single-pool Kt/V, ultrafiltration, HD duration or blood liters processed.

Conclusions

Cystatin C is very elevated in children on HD. It does not rise between HD sessions, is not removed by standard HD and remains at steady state; therefore, elimination is extrarenal. Low RRF does not affect CyC elimination. CyC increases with age and height. If a high CyC concentration can be proven to have a causative role in the development of CVD, routine intensified HD regimens in children may be indicated for its removal.

Sharma AP, Kathiravelu A, Nadarajah R, Yasin A, Filler G (2009) Body mass does not have a clinically relevant effect on cystatin C eGFR in children. Nephrol Dial Transplant 24:470–474PubMedCrossRef

Huang SH, Filler G, Yasin A, Lindsay RM (2011) Cystatin C reduction ratio depends on normalized blood liters processed and fluid removal during hemodialysis. Clin J Am Soc Nephrol 6:319–325PubMedCrossRef

Zaffanello M, Franchini M, Fanos V (2007) Is serum Cystatin-C a suitable marker of renal function in children? Ann Clin Lab Sci 37:233–240PubMed

Tenstad O, Roald AB, Grubb A, Aukland K (1996) Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 56:409–414PubMedCrossRef

Bacchetta J, Cochat P, Rognant N, Ranchin B, Hadj-Aissa A, Dubourg L (2011) Which creatinine and cystatin C equations can be reliably used in children? Clin J Am Soc Nephrol 6:552–560PubMedCrossRef

Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators CKD-EPI (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20–29PubMedCrossRef

Sjöström P, Tidman M, Jones I (2005) Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 65:111–124PubMedCrossRef

Sjöström PA, Jones IL, Tidman MA (2009) Cystatin C as a filtration marker: haemodialysis patients expose its strengths and limitations. Scand J Clin Lab Invest 69:65–72PubMedCrossRef

Andersen TB, Jødal L, Boegsted M, Erlandsen EJ, Morsing A, Frøkiær J, Brøchner-Mortensen J (2011) GFR prediction from Cystatin C and Creatinine in children: effect of including body cell mass. Am J Kidney Dis 59:50–57PubMedCrossRef

10.

Sharma AP, Yasin A, Garg AX, Filler G (2011) Diagnostic accuracy of Cystatin C–based eGFR equations at different GFR levels in children. Clin J Am Soc Nephrol 6:1599–1608PubMedCrossRef

11.

Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, Balko JA, Gupta S, Mammen PP, Drazner MH, Markham DW (2009) Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2:98–104PubMedCrossRef

12.

Codoñer-Franch P, Ballester-Asensio E, Martínez-Pons L, Vallecillo-Hernández J, Navarro-Ruíz A, Valle-Pérez R (2011) Cystatin C, cardiometabolic risk, and body composition in severely obese children. Pediatr Nephrol 26:301–307PubMedCrossRef

13.

Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115:173–179PubMedCrossRef

14.

Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ (2007) Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 147:19–27PubMed

15.

Shin MJ, Song SH, Kwak IS, Lee SB, Lee DW, Seong EY, Kim IY, Rhee H, Lee N (2012) Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis. Clin Exp Nephrol 16:456–463PubMedCrossRef

16.

Imai A, Komatsu S, Ohara T, Kamata T, Yoshida J, Miyaji K, Shimizu Y, Takewa M, Hirayama A, Deshpande GA, Takahashi O, Kodama K (2011) Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. Atherosclerosis 218:350–355PubMedCrossRef

17.

Taglieri N, Koenig W, Kaski JC (2009) Cystatin C and cardiovascular risk. Clin Chem 55:1932–1943PubMedCrossRef

18.

Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lindsay RM (2009) Cystatin C levels in functionally anephric patients undergoing dialysis: the effect of different methods and intensities. Clin J Am Soc Nephrol 4:1606–1610PubMedCrossRef

19.

Park JS, Kim GH, Kang CM, Lee CH (2010) Application of Cystatin C reduction ratio to high-flux Hemodialysis as an alternative indicator of the clearance of middle molecules. Korean J Intern Med 25:77–81PubMedCrossRef

20.

Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, Wanner C, Canaud B (2010) Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 25:212–218PubMedCrossRef

21.

Lindstrom V, Grubb A, Hegbrant MA, Christensson A (2008) Different elimination patterns of b-trace protein, b2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scand J Clin Lab Invest 68:685–691PubMedCrossRef

22.

Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT (2007) Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant 22:1633–1638PubMedCrossRef

23.

Kim SJ, Sohn YB, Park SW, Jin DK, Paik KH (2011) Serum Cystatin C for estimation of residual renal function in children on peritoneal dialysis. Pediatr Nephrol 26:433–440PubMedCrossRef

24.

Filler G, Huang SS, Lindsay RM (2011) Residual renal function assessment with cystatin C. Pediatr Nephrol 26:333–335PubMedCrossRef

25.

Goldstein SL, Currier H, Watters L, Hempe JM, Sheth RD, Silverstein D (2003) Acute and chronic inflammation in pediatric patients receiving hemodialysis. J Pediatr 143:653–657PubMedCrossRef

26.

Grubb A, Björk J, Nyman U, Pollak J, Bengzon J, Ostner G, Lindström V (2011) Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest 71:145–149PubMed

27.

Özden TA, Tekerek H, Bafl F, Darendeliler F (2010) Effect of hypo-and euthyroid status on serum cystatin C levels. J Clin Res Ped Endo 2:155–158CrossRef

28.

Manetti L, Pardini E, Genovesi M, Campomori A, Grasso L, Morselli LL, Lupi I, Pellegrini G, Bartalena L, Bogazzi F, Martino E (2005) Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 28:346–349PubMed

29.

European best practice guidelines for haemodialysis (part 1) (2002) Measurement of residual renal function in HD. Nephrol Dial Transplant 17:11–15

30.

Gehan E, George SL (1970) Estimation of human body surface area from height and weight. Cancer Chemother Rep 54:225–235PubMed

31.

Daugirdas JT (1993) Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4:1205–1213PubMed

32.

KDOQI Clinical practice guidelines for hemodialysis adequacy (2006) Guideline 3. Methods for postdialysis blood sampling. Am J Kidney Dis 48:S24–S27

33.

Fischbach M, Fothergill H, Zaloszyc A, Menouer S, Terzic J (2011) Intensified daily dialysis: the best chronic dialysis option for children? Semin Dial 24:640–644PubMedCrossRef

34.

Fischbach M, Fothergill H, Zaloszyc A, Seuge L (2012) Hemodiafiltration: the addition of convective flow to hemodialysis. Pediatr Nephrol 27:351–356PubMedCrossRef

35.

Fischbach M, Hamel G, Koehl C, Geisert J (1989) Beta-2-microglobulin in hemodiafiltered children: long-term efficiency follow-up. Nephron 53:110–114PubMedCrossRef

36.

Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Brodehl J (1998) Reference values for cystatin C serum concentrations in children. Pediatr Nephrol 12:125–129PubMedCrossRef

37.

Köttgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J (2008) Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 51:385–394PubMedCrossRef

38.

Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578–585PubMedCrossRef

39.

North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) (2011) Dialysis patient characteristics. In: NAPRTCS (ed) Annual dialysis report. NAPRTCS, Boston, pp 1–18

40.

Newman DJ (2002) Cystatin C. Ann Clin Biochem 39:89–104PubMedCrossRef

41.

Bökenkamp A, Herget-Rosenthal S, Bökenkamp R (2006) Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 21:1223–1230PubMedCrossRef

Title: Cystatin C in children on chronic hemodialysis
Authors: Olivera Marsenic
Andrea Wierenga
Donna R. Wilson
Michael Anderson
Tripti Shrivastava
Garfield A. Simon
Anne M. Beck
Tiffany J. Swanson
Kathleen Studnicka
Dorit Elberg
Kevin Couloures
Martin A. Turman
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 4/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-012-2366-7

At a glance: The STEP trials

Springer Medicine

Cystatin C in children on chronic hemodialysis

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

Ghrelin and cachexia in chronic kidney disease

Hypophosphatemia and growth

Nutritional management and growth in children with chronic kidney disease

FGF23 production by osteocytes

Searching the optimal PTH target range in children undergoing peritoneal dialysis: New insights from international cohort studies

Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome